Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
NASDAQ:CLPT

ClearPoint Neuro Q3 2026 Earnings Date & Estimates

ClearPoint Neuro logo
$10.48 -0.01 (-0.10%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$10.68 +0.20 (+1.91%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ClearPoint Neuro is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from ClearPoint Neuro in Q3 2026

ClearPoint Neuro is expected to post earnings of -$0.27 per share on revenue of $12.30 million. In the same quarter a year earlier ClearPoint Neuro reported -$0.21 per share on revenue of $5.36 million. ClearPoint Neuro last reported on August 3, 2026, posting -$0.38 per share and missing the -$0.2867 consensus estimate. ClearPoint Neuro has beaten the consensus EPS estimate in 0 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.27
Expected Revenue
$12.30 million
Prior-Year EPS
-$0.21
Prior-Year Revenue
$5.36 million
Expected Revenue Growth
+129.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.38 (Missed by -$0.0933)
Last Quarter Revenue
$10.88 million
EPS Beat Rate
0 of last 8 quarters

Prepare for the Q3 2026 Call

ClearPoint Neuro Q3 2026 Earnings FAQ

ClearPoint Neuro (NASDAQ:CLPT) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes.

ClearPoint Neuro's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect ClearPoint Neuro to post earnings of -$0.27 per share for Q3 2026.

The consensus revenue estimate for ClearPoint Neuro is $12.30 million for Q3 2026.

ClearPoint Neuro Earnings Headlines

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
October 8 at 10:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-clearpoint-neuro-inc---clpt-302902097.html
CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law
October 7, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261007540042/en/clpt-investors-with-100000-in-losses-have-opportunity-to-join-clearpoint-neuro-inc.-fraud-investigation-with-sbs-law/
The Executive Order That Quietly Changed What Your Dollar Means
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
October 11 at 1:00 AM  |  Reagan Gold Group (Ad)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3376136/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-clearpoint-neuro-inc-clpt.html
Head to Head Analysis: IceCure Medical (NASDAQ:ICCM) vs. ClearPoint Neuro (NASDAQ:CLPT)
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085542
ClearPoint Neuro: My Speculative Buy Didn't Pan Out, Moving To Hold
October 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951380-clearpoint-neuro-speculative-buy-didnt-pan-out-moving-to-hold
See More ClearPoint Neuro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ClearPoint Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ClearPoint Neuro and other key companies, straight to your email.

About ClearPoint Neuro

ClearPoint Neuro (NASDAQ:CLPT) is a medical technology company that develops and commercializes image-guided systems for minimally invasive neurosurgical procedures. Its platform is designed to help physicians plan, navigate and monitor procedures within the brain, using magnetic resonance imaging (MRI) to support accurate placement of instruments and therapeutic agents.

The company’s product portfolio includes the ClearPoint Neuro navigation system and related disposable components, including cranial access and guidance products. These technologies are used in procedures such as biopsies, laser ablation, deep brain stimulation lead placement and the delivery of drugs or gene therapies directly to targeted areas of the brain. ClearPoint Neuro also provides planning, software and procedural support services for hospitals, research institutions and pharmaceutical or biotechnology companies developing neurological treatments.

The company was formerly known as MRI Interventions, Inc. and adopted the ClearPoint Neuro name in 2020. Its technologies are used primarily in the United States, with international activities supported through commercial and research relationships. ClearPoint Neuro is headquartered in Solana Beach, California, and serves the neurosurgical, pharmaceutical and biotechnology markets.

View ClearPoint Neuro Profile
Earnings Tools